Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
38.90
0.00 (0.00%)
Dec 31, 2025, 4:00 PM EST - Market closed
Castle Biosciences Employees
Castle Biosciences had 761 employees as of December 31, 2024. The number of employees increased by 151 or 24.75% compared to the previous year.
Employees
761
Change (1Y)
151
Growth (1Y)
24.75%
Revenue / Employee
$451,419
Profits / Employee
-$16,079
Market Cap
1.14B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 761 | 151 | 24.75% |
| Dec 31, 2023 | 610 | 67 | 12.34% |
| Dec 31, 2022 | 543 | 198 | 57.39% |
| Dec 31, 2021 | 345 | 144 | 71.64% |
| Dec 31, 2020 | 201 | 66 | 48.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CSTL News
- 14 days ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma - GlobeNewsWire
- 21 days ago - Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer - GlobeNewsWire
- 24 days ago - Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma - GlobeNewsWire
- 6 weeks ago - Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year - GlobeNewsWire
- 7 weeks ago - New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity - GlobeNewsWire
- 7 weeks ago - Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Why Castle Biosciences' Rally Might Just Be Getting Started - Benzinga